

# ESRD Billing for J0406 or J0606 with Modifier AX

### **Purpose**

This policy is intended to ensure correct provider reimbursement and serves only as a general resource regarding Molina Healthcare's reimbursement policy for the services described in this policy. It is not intended to address every aspect of a reimbursement situation, nor is it intended to impact care decisions. This policy was developed using nationally accepted industry standards and coding principles. In a conflict, federal and state guidelines, as applicable, and the member's benefit plan document supersede the information in this policy. Also, to the extent of conflicts between this policy and the provider contract language, the Provider contract language will prevail. Coverage may be mandated by applicable legal requirements of a State, the Federal government or the Centers for Medicare and Medicaid Services (CMS). References included were accurate at the time of policy approval.

#### Overview

An edit will fire on End Stage Renal Disease claims on Type of Bill (TOB) 072X if modifier AX is present on HCPCS codes J0604 or J0606. This is based on a requirement from the Centers for Medicare and Medicaid Services (CMS). Per CMS, modifier AX cannot be billed with HCPCS codes J0604 or J0606.

### **Policy**

Modifier AX is used in ESRD facilities to indicate that an item or service was furnished in conjunction with dialysis services. It is used with HCPCS codes for equipment, CRA, and drugs or biologicals to receive payment for these items or services using the TDAPA.

The Transitional Drug Add-on Payment Adjustment (TDAPA) is a payment adjustment under the ESRD PPS for certain new renal dialysis drugs and biological products. TDAPA requirements are set forth in the ESRD PPS regulations at 42 C.F.R. § 413.234.

Per CMS Transmittal R10568BP, <u>Implementation of Changes in the End-Stage Renal Disease (ESRD)</u>

<u>Prospective Payment System (PPS) and Payment for Dialysis Furnished for Acute Kidney Injury (AKI) in ESRD</u>

<u>Facilities for Calendar Year (CY) 2021</u>, *dated January 14, 2021*, "Effective January 1, 2021, calcimimetics are no longer paid for under the ESRD PPS using the TDAPA."

In addition, the transmittal advises, "Discontinue processing the TDAPA for J0604 and J0606 when billed with modifier AX on Type of Bill 72X for from dates on or after January 1, 2021."

12011.6: Medicare contractors shall update the TDAPA codes:

- Discontinue processing the TDAPA for J0604 and J0606 when billed with modifier AX on Type of Bill 72X for from dates on or after January 1, 2021.
- No new drugs being added.

### **Procedure Codes (CPT & HCPCS)**

Code	Code Description
J0604	Cinacalcet, oral, 1 mg, (for ESRD on dialysis)
J0606	Injection, etelcalcetide, 0.1 mg

## **Documentation History**



Туре	Date	Action
Effective Date		New Policy
Revised Date		

### References

#### **Government Agencies**

https://www.cms.gov/files/document/r10568bp.pdf

 $\underline{https://www.cms.gov/files/document/mm12583-quarterly-update-end-stage-renal-disease-prospective-payment-system-esrd-pps.pdf}$ 

# **Supplemental Information**

### **Definitions**

Term	Definition		
Modifier AX	Item furnished in conjunction with dialysis services		
TDAPA The Transitional Drug Add-on Payment Adjustment (TDAPA) is a payr			
	adjustment under the ESRD PPS for certain new renal dialysis drugs and		
	biological products		
ESRD	End-Stage Renal Disease		
HCPCS	Healthcare Common Procedure Coding System		
CRA	Capitol Related Assets Adjustment under TDAPA		